CD274 and Tumor Lysis Syndrome: The incidence of TLS associated with anti‐programmed death receptor‐1 (PD‐1) and anti‐programmed death ligand‐1 (PD‐L1) therapies has increased, from 10 cases in 2015 to 42 cases in 2020.